Supporting the role of the United States in helping save the lives of children and protecting the health of people in low-income countries with vaccines and immunization through Gavi, the Vaccine Alliance ("Gavi").

International Affairs
house

Introduced on June 11, 2024 by Thomas Kean

Cosponsors (38)

Legislation Details

  • Supports the role of the U.S. in aiding low-income countries through vaccines and immunization with Gavi, the Vaccine Alliance.
  • Highlights the decline in vaccine distribution and resources before 2000, leading to high child mortality rates.
  • Emphasizes the importance of vaccines in preventing diseases and contributing to economic growth and poverty reduction.
  • Credits Gavi, since its inception in 2000, with immunizing over 1 billion children and averting an estimated 17.3 million deaths.
  • Notes a 70% reduction in childhood deaths from vaccine-preventable diseases in lower-income countries since 2000.
  • Discusses Gavi’s model of country ownership and sustainability, with countries co-financing vaccine costs.
  • Mentions Gavi’s role in making vaccines more affordable and increasing the number of vaccine manufacturers.
  • Highlights Gavi’s efforts in market shaping, expected to save over $900 million from 2021 to 2025.
  • Describes Gavi’s comprehensive support for 18 vaccines and its collaboration with various organizations to improve vaccine manufacturing and distribution.
  • Details Gavi’s involvement in combating diseases like polio, cholera, measles, yellow fever, Ebola, and malaria.
  • Outlines Gavi’s support for health system strengthening and its response to the COVID-19 pandemic through COVAX.
  • Acknowledges the high impact and cost-effectiveness of vaccine programs, with a return of over $50 for every $1 invested in Gavi-supported countries.
  • Affirms the U.S. government’s support for Gavi’s goals and recognizes the need for continued U.S. commitment and investment in Gavi’s future strategic periods.

Last updated 11/19/2024